Hydroxyurea for Children with Sickle Cell Disease: A Practical Guide for Pediatric Clinicians

Area of Science:

• Pediatric Hematology
• Sickle Cell Disease Management
• Pharmacotherapy

Background:

• Hydroxyurea is the standard treatment for pediatric sickle cell disease (SCD).
• It is particularly recommended for sickle cell anemia (SCA) from infancy throughout childhood.
• Evidence for its use in HbSC and HbSß⁺ SCD with frequent complications is limited but suggests potential benefits.

Purpose of the Study:

• To emphasize the critical role of hydroxyurea in managing pediatric sickle cell disease.
• To highlight the importance of early and continuous hydroxyurea treatment in children with sickle cell anemia.
• To address the need for improved adherence and accessibility of hydroxyurea therapy.

Main Methods:

• Review of current treatment guidelines and evidence for hydroxyurea in pediatric SCD.
• Analysis of the benefits of hydroxyurea in reducing complications in various SCD genotypes.
• Discussion of barriers to hydroxyurea initiation and maintenance.

Main Results:

• Hydroxyurea significantly reduces acute complications and chronic organ damage in children with sickle cell anemia.
• Potential benefits of hydroxyurea in reducing complications in children with HbSC and HbSß⁺ are noted, though evidence is limited.
• Barriers to hydroxyurea use necessitate collaborative care models.

Conclusions:

• Hydroxyurea is foundational for managing children with sickle cell anemia.
• A collaborative approach between primary care pediatricians and sickle cell specialists is crucial.
• This partnership can overcome barriers to starting and maintaining hydroxyurea treatment, improving outcomes for children with SCD.